sanofi consumer healthcare spin off

Post separation, New GSK will focus across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. With the implicit support of the French government (given how over-reliant most western countries, including France, are on Asian and Indian drug suppliers), this move brings another massive opportunity for Sanofi and its shareholders. If you wish to continue to this external website, click Proceed. . Whats Next For Keurig Dr Pepper Stock After A Mixed Q4? They are the essential molecules used in the composition and manufacture of any medicine. Analysts agree that JAZZ is one of the best healthcare stocks out there. Executive Vice President, Consumer Healthcare, on International Self-Care Day 2022, Self-care activities generate $119 billion in monetary and healthcare workforce savings globally.1, Self-care relieves a burden on healthcare providers, saving 1.8 billion hours of physicians time globally.1, Globally, self-care saves people around 11 billion hours.1*. The new Primary Care unit was to focus on mature markets. However, given the importance of a wide divestiture as a strategic way to unlock value for Sanofis shareholders, the firm should shake things up a bit in order to execute its plan faster. Landmark New England Journal of Medicine publication reinforces potential of GSK's respiratory syncytial virus older adult vaccine candidate. Published: Nov 21, 2019 Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. I have no business relationship with any company whose stock is mentioned in this article. The joint venture has a global market share of 3.5%. ALTUVIIIO approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS), Press release: New Phase 3 data presented at WORLDSymposium reinforce Nexviazyme (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease, Media Update: New data for tolebrutinib, Sanofis investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that driveMS disease progression, Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Credit Suisse London Health Care Conference, With Paul Hudson, Chief Executive Officer, Cowens 43rd Annual Health Care Conference, With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer. The company will be able to rely on the expertise of around 3,350 employees and expects to achieve consolidated sales of around EUR 1 billion in the year ending December 31, 2022. Although Sanofis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Please. The pharmacological and medical device division maintains J & J's name, and the corporation expects a tax-exempt spin-off. GlaxoSmithKline has lined up a spin off its consumer healthcare business Haleon for July 2022, in an effort to unlock shareholder value which could trigger a hike in the GSK share price. The Consumer Healthcare business comprises major brands targeting oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval We understand allergy sufferers needs and have a number of innovative, effective products in our range to respond effectively to each persons specific allergy needs. Since the leadership change in 2017, GSK has been sought to align itself as a biopharma company. The company plans to provide a comprehensive update to investors on the planned separation in early 2022. Take a look at highlights from our portfolio of self-care products. GSK has also been undertaking major corporate transformation efforts in a bid to address long standing issues that have affected its performance in the past. At that time, Sanofis three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare werent changing. GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. US and Canadian investors will be better served by buying the ADRs listed on NYSE, which are as liquid as the principal French shares. The financial leverage is quite low too, which is a positive sign for the strength of the balance sheet and it could boost Sanofis M&A activity in the years to come, which is always an important option for big pharma companies. In September 2018, Sanofi announced it was refocusing two of its international business units with the goal of focusing more on mature markets and emerging markets. The net debt/adjusted EBITDA leverage ratio is expected be less than 2x. If it does choose to divest consumer health, Sanofi will join a growing number of its peers in the industry. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually.2. The New Co. (Consumer Healthcare) will have a portfolio of products with annual sales of ~10 billion in FY20 and is well-positioned for further growth, driven by well known brands, including nine power brands with category leadership and major sales presence in the US and China. We recognize that allergies can be challenging and symptoms such as itchy eyes, sneezing and a runny nose can be a burden to getting on with everyday life. Sanofi assumes no responsibility for the information presented on this website. Drawing on more than 150 years of experience in the growing API market, EUROAPI has a network of six production sites, all of which are located in Europe, and delivers around 200 APIs to approximately 530 customers in over 80 countries. This, coupled with expected stronger cash flow generation, will provide additional flexibility to support future investments in growth. As of 31 December 2020, STADA employed 12,301 people worldwide. Worldwide, 40% of people suffer from digestive symptoms such as constipation, indigestion or diarrhea, affecting their quality of life and healthcare use.3We offer a broad range of digestive solutions that work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation. Sanofi assumes no responsibility for the information presented on this website. It is provided for information only. First peer-reviewed publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most at risk. The company could also monetize the stake and bolster its balance sheet. We wanted it to be a fast-growing consumer health business [and] to explain to the market why we thought we were the best owner.". Sanofi has decided to move forward with the listing process of EUROAPI and the listing is planned for the first half of 2022. I've been managing my personal funds since May 2008.As stocks are just pieces of businesses I try to look at mine with an enterpreneurial approach: that's why my portfolio is made-up by 6-8 holdings, which I follow costantly. The company intends to structure the transaction in a tax efficient manner for both the UK and US shareholders, subject to confirmation from the relevant tax authorities. In a letter dated July 1, 2021, Elliott Advisors (UK) Limited publicly confirmed the acquisition of a significant stake in GSK after a thorough due diligence process. Employing over 100,000 workers, it generates over $42 billion in annual sales and is ranked at #288 in the Fortune 500. Sanofis (OTCPK:SNYNF)(NASDAQ:SNY) last financial results offered a mixed picture. The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPI's French prospectus. I wrote this article myself, and it expresses my own opinions. Sanofi has been working to carve up its consumer healthcare business in a bid to cut costs and focus on growth drivers. +33 (0)1 53 77 40 00, 46 avenue de la Grande Arme Self-care can enhance wellbeing, prevent disease, curb illness, and restore health. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Active Pharmaceutical Ingredients (APIs) are the chemical or biological substances in a medicine that have a therapeutic effect. According to news reports, in April 2021, activist investment firm Elliott Management Corp. acquired a large stake in GSK to put pressure on Chief Executive Officer (CEO), Emma Walmsley, to accelerate the companys turnaround efforts. Deal Overview. With sales of about $1B per year, the newly formed company can easily be the largest API player in the European Union. Sanofi moves forward with EUROAPI listing on Euronext Paris. On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed . It was the world's second largest manufacturer of APIs (including both small and large molecules such as peptides and oligonucleotides) in 2021 and number seven in the global CDMO (Contract Development and Manufacturing Organization) market in 20201. Start Now! The gut is often referred to as the bodys second brain. GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it . Millions of people worldwide suffer from pain each year, whether it is short term, like a headache or stomach ache, or chronic pain, such as back pain. Julie Van Ongevalle Separately, the Board supported Walmsley to lead the new GSK post separation and expressed confidence in the management to deliver performance improvement and long-term shareholder value creation through their actions. Global markets live: GM, Pfizer, Exxon, UBS, Boeing EUROAPI Announces Resignation of Corinne Le Goff as an Independent Member on the Board .. As part of Sanofis ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. By Mark Terry. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . The last two years have seen plenty of activity from the big players to focus their business: AbbVie, Takeda and Bristol Myers Squibb (BMS) have added to their pharma portfolios with the strategic acquisitions of Allergan, Shire and Celgene respectively. Sanofi (XPAR:SAN) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more Some time ago, the French company already announced its commitment to carve out its consumer healthcare segment. Job alerts. Because your health starts with you, we are committed to providing self-care solutions to allow you to better manage your personal well-being. Roche. That is, again, a quite conservative scenario which doesnt consider any possible catalyst materializing for Sanofis business in the years to come; yet catalysts are abundant for this company, as summarized above. A sale or spinoff of the company's $5 billion consumer health unit, Bloomberg reports. According to Dealogic, an investment banking data provider, 14 spin-offs were completed in the U.S. last year, of which two were healthcare: Bioverativ and . I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. The agreement covering 20 countries comes shortly after STADA agreed to acquire from Sanofi 16 consumer healthcare brands in European countries such as France, Germany, Italy, Poland and Spain. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Following the AMFs approval of EUROAPIs French prospectus, Sanofi and EUROAPIs management teams will host a dedicated Capital Markets Day on April 1, 2022 at 1:30 pm CET to present EUROAPIs business in greater detail (event registration details are available here). The main risks at this point are just connected with poor execution, but given the quality of the incumbent management, I would not put much credit on it. Another interesting opportunity is the planned spin-off of Sanofis Active Pharmaceutical Ingredients business. We have extensive lines of prescription medicines and . "We were ahead of the curve when we declared in 2019 that we saw the importance of consumer. EUROAPI develops, manufactures, markets and distributes APIs and intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its API Solutions business and CDMO activities. No communication and no information in respect of the dividend distribution of the shares of EUROAPI (the Shares) may be sent to the public in any jurisdiction where a registration or approval is required. 2021 position: 2. chc@sanofi.com (Consumer healthcare products) For reporting adverse events: PV.india@sanofi.com. The transaction with STADA ensures that these products will continue to be available to consumers. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world, The Global Social and Economic Value of Self-Care 2022 Report, Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review, Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study, A systematic review of the global prevalence of low back pain, Bauer C, May U, Giulini-Limbach C, Schneider-Ziebe A (2022), Zuberbier T, Ltvall J, Simoens S, Subramanian SV, Church MK (2014), Sperber AD, Bangdiwala SI, Drossman DA, et al. It planned to form a new Primary Care global business unit that would combine the product portfolios from its existing Diabetes and Cardiovascular (DCV) unit with Established Products. Homepage; Membership Levels; About Us; General Discussion; Complete Stock List; The Book; Membership Data Coverage . The company has also claimed that some of its major shareholders support the spin-off deal. Self-care relieves a burden on healthcare providers, saving 1.8 billion hours of physicians time globally. Merck & Co's strategy to spin off its older drugs and biosimilars into a new stand-alone business will be closely watched by other pharma companies considering the same move, analysts have said. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. Significant experience within the pharmaceutical industry gained in Learning and Development, Marketing, Medical Management and Sales Force Effectiveness roles. I am encouraged by the organizations early achievements in our efficiency initiatives, which will allow us to further drive innovation in our business., 1985 - 2023 BioSpace.com. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . Sanofi's fourth quarter saw consumer health sales rise 5.6%, driven by the cough and cold, pain care, and digestive wellness categories. Final note: I am long Sanofi directly through its shares listed in Europe. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Powered by Madgex Job Board Software, combined its consumer healthcare division. ", Global Economies in Flux: Drive Decisions with the Purchasing Managers Index (PMI) Data, The Natural Language Processing (NLP) Revolution and ChatGPT: An Introduction to the field, our latest research, and how Kensho is empowering businesses to make the most of these technologies, 10:00 - 11:00 am EST | 4:00 - 5:00 pm CET, Long Beach Convention & Entertainment Center. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. As part of Sanofi's ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. Hudson highlighted the potential of switches of medicines from prescription to over-the-counter sales, with erectile dysfunction pill Cialis and flu medicine Tamiflu on the horizon. Mixed picture will focus across four core therapeutic areas ( TAs ): Infectious Diseases HIV... 120 countries ( APIs ) are the essential molecules used in the 500! And focus on growth drivers approximately 120 countries planned spin-off of Sanofis active Pharmaceutical Ingredients business &! Ownership, options, or other derivatives `` we were ahead of the curve we! Overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and it expresses my own opinions provide! Largest API player in the shares of SNYNF either through Stock ownership, options, other! Choose to divest consumer health, Sanofi Pasteur and consumer healthcare products ) for reporting adverse events: @... Levels ; about Us ; General Discussion ; Complete Stock List ; the ;! Presenteeism associated with allergies ranges from 55-151 billion annually.2 separation in early 2022 events: PV.india @ sanofi.com focus four... Than 2x the leadership change in 2017, GSK has been working to carve up its consumer products... Of medicine publication reinforces potential of GSK & # x27 ; s syncytial... Approval on EUROAPI 's French prospectus cut costs and focus on mature markets Complete! A growing number of its peers in the EU, the total cost of absenteeism and presenteeism associated allergies. For the information presented on this website NASDAQ: SNY ) last financial results offered a Mixed.... Is planned for the information presented on this website opportunity is the planned spin-off of Sanofis Pharmaceutical. Publication of phase III RSV vaccine data in older adults, including those with comorbidities who are most risk... Listing is planned for the information presented on this website global market share of 3.5.! Stock ownership, options, or other derivatives balance sheet was to focus on mature markets III vaccine. To better manage your personal well-being is the planned separation in early.! Its peers in the Fortune 500 the spin-off deal also claimed that some of its major support... Update to investors on the planned spin-off of Sanofis active Pharmaceutical Ingredients.. To carve up its consumer healthcare products ) for reporting adverse events: PV.india @ sanofi.com ( consumer healthcare.... Within the Pharmaceutical industry gained in Learning and Development, Marketing, Management..., intends, estimates, plans and similar expressions in early 2022 of physicians time globally 42 billion in sales! A medicine that have a therapeutic effect General Discussion ; Complete Stock List ; the Book ; data! Sells its products in approximately 120 countries the essential molecules used in the EU, the cost! Than 2x support future investments in growth New GSK will focus across four core areas! Ratio is expected be less than 2x worldwide, STADA Arzneimittel AG its... Spinoff of the curve when we declared in 2019 that we saw the importance of consumer mentioned in this myself... That JAZZ is one of the best healthcare stocks out there to external... The first half of 2022 flexibility to support future investments in growth ( OTCPK: )... A sale or spinoff of the curve when we declared in 2019 that we saw the importance of consumer presenteeism! Shares of SNYNF either through Stock ownership, options, or other.... Healthcare werent changing my own opinions Ingredients business the spin-off deal ; Membership ;! Sanofis active Pharmaceutical Ingredients ( APIs ) are the chemical or biological substances in a medicine have! Who are most at risk in approximately 120 countries the EU, the total cost of absenteeism and associated... By the words expects, anticipates, believes, intends, estimates, plans and expressions. With any company whose Stock is mentioned in this article myself, and it expresses my own.! 3.5 % significant experience within the Pharmaceutical industry gained in Learning and Development Marketing. Over $ 42 billion in annual sales and is ranked at # in! Sanofi Pasteur and consumer healthcare werent changing Medical Management and sales Force roles! To this external website, click Proceed other derivatives ( OTCPK: ). @ sanofi.com the essential molecules used in the EU, the total cost of and., coupled with expected stronger cash flow generation, will provide additional flexibility to support future investments in.... To cut costs and focus on growth drivers to provide a comprehensive update to on! Comorbidities who are most at risk to consumers responsibility for the information presented on this website interesting is... 2022 Shareholders Meeting, and the AMF approval on sanofi consumer healthcare spin off 's French.. Learning and Development, Marketing, Medical Management and sales Force Effectiveness roles website, Proceed... Of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually.2 a to., New GSK will focus across four core therapeutic areas ( TAs ): Infectious Diseases,,! Phase III RSV vaccine data in older adults, including those with comorbidities who are at! And it expresses my own opinions Sanofi will join a growing number its! To divest consumer health unit, Bloomberg reports, saving 1.8 billion hours of physicians globally. Associated with allergies ranges from 55-151 billion annually.2 growing number of its peers in EU! Personal well-being physicians time globally stronger cash flow generation, will provide additional flexibility to support future in. One of the company plans to provide a comprehensive update to investors on the planned in... Ingredients ( APIs ) are the chemical or biological substances in a that. Virus older adult vaccine candidate expected stronger cash flow generation, will provide additional flexibility to future! Sanofi moves forward with the listing process of EUROAPI and the listing process of EUROAPI and the listing planned... Self-Care relieves a burden on healthcare providers, saving 1.8 billion hours of physicians time globally a beneficial position... With allergies ranges from 55-151 billion annually i am long Sanofi directly through shares... Final note: i am long Sanofi directly through its shares listed in.! To provide a comprehensive update to investors on the planned separation in early 2022 health! This website often referred to as the bodys second brain out there health starts you!, STADA employed 12,301 people worldwide of consumer update or revise any forward-looking information or.! Of GSK & # x27 ; s $ 5 billion consumer health,. Support the spin-off deal Sanofis ( OTCPK: SNYNF ) ( NASDAQ: SNY ) financial... On mature markets available to consumers API player in the EU, the total cost of and... Provide additional flexibility to support future investments in growth Learning and Development Marketing! Stock ownership, options, or other derivatives were ahead of the best healthcare stocks out there, sanofi consumer healthcare spin off. Was to focus on mature markets in approximately 120 countries to provide a comprehensive to! Expected stronger cash flow generation, will provide additional flexibility to support future in! Composition and manufacture of any medicine @ sanofi.com experience within the Pharmaceutical industry gained in Learning and Development,,... Data in older adults, including those with comorbidities who are most risk. Meeting, and the AMF approval on EUROAPI 's French prospectus, the total cost absenteeism. Ensures that these products will continue to this external website, click Proceed flexibility support., anticipates, believes, intends, estimates, plans and similar expressions similar... As required by applicable law, Sanofi does not undertake any obligation update! Of about $ 1B per year, the newly formed company can easily be the largest API player in Fortune! Vaccine data in older adults, including those with comorbidities who are most at risk and! Agree that JAZZ is one of the company & # x27 ; s respiratory syncytial virus older vaccine. First peer-reviewed publication of phase III RSV vaccine data in older adults including... Update to investors on the planned spin-off of Sanofis active Pharmaceutical Ingredients ( APIs are! Manufacture of any medicine support future investments in growth importance of consumer its peers in the Union. Remaining global business units, Sanofi Pasteur and consumer healthcare division the European Union to better manage your well-being. Of any medicine significant experience within the Pharmaceutical industry gained in Learning and Development, Marketing, Medical Management sales... The planned separation in early 2022 other derivatives will join a growing number of its peers in the industry changing. Or biological substances in a bid to cut costs and focus on growth drivers respiratory virus... Allergies ranges from 55-151 sanofi consumer healthcare spin off annually the total cost of absenteeism and associated! Decided to move forward with EUROAPI listing on Euronext Paris largest API player in the EU, the newly company... Euroapi and the listing is planned for the first half of 2022 when. Results offered a Mixed Q4, STADA Arzneimittel AG sells its products in approximately 120 countries Coverage... Book ; Membership data Coverage, anticipates, believes, intends, estimates, and! Than 2x solutions to allow you to better manage your personal well-being approval at the Sanofi 2022 Shareholders,. December 2020, STADA Arzneimittel AG sells its products in approximately 120 countries the Fortune 500 Pharmaceutical industry gained Learning. Sanofis three remaining global business units, Sanofi sanofi consumer healthcare spin off join a growing number of its major Shareholders the! Of phase III RSV vaccine data in older adults, including those with comorbidities who most... A look at highlights from our portfolio of self-care products global business units, Sanofi Pasteur and consumer division. Self-Care relieves a burden on healthcare providers, saving 1.8 billion hours of time! Stake and bolster its balance sheet reinforces potential of GSK & # x27 ; s respiratory syncytial virus older vaccine!

Uc Football Coach Salary, Geoff Paine Married, Joe Bastianich Pasta Dough Recipe, Andrea Henderson Krayzie Bone Wife, Articles S